Sinsin Pharmaceutical Co., Ltd.
KKRX:0028004,080.00
KRW
-75.00
(-1.81%)
ISIN
KR7002800001
Return %
Stock
S&P 500
1Y
-23.74
14.39
3Y
-28.17
81.42
5Y
-42.54
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Byung-Gi Lee
- Full Time Employees
- 369
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Sejong-si South Korea
- IPO Date
- Feb 28, 2017
- Website
- sinsin.com
- Similar Companies
- Business
- Sinsin Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacturing, and commercialization of over-the-counter (OTC) medications, prescription pharmaceuticals, medical devices, and consumer healthcare products specializing in transdermal drug delivery systems (TDDS). Founded in 1959 and headquartered in Sejong, South Korea, with research and administrative operations centered at its Magok R&D Center in Seoul, the company distributes its products domestically to wholesale distributors, hospitals, and retail pharmacies, while maintaining export operations across North America, Central and South America, Southeast Asia, and Greater China. The company organizes its product offerings across therapeutic and consumer categories; its core portfolio includes topical analgesic and anti-inflammatory transdermal patches under flagship brand names such as Sinsin Pas, Sinsin Pas Arex, and Sinsin Pas RX; liquid roll-on analgesics including Mulpas; aerosol pain-relief sprays, ointments, lotions, and gels; wound care and first-aid supplies comprising hydrocolloid bandages, adhesive plasters, and surgical tapes; topical antifungal agents; anti-itch and insect bite remedies; insect repellent sprays; and pediatric cooling sheets. In recent operational and strategic developments, Sinsin Pharmaceutical has accelerated its transformation into a specialized biotechnology and drug delivery enterprise by advancing proprietary transdermal and microneedle therapeutic pipelines, including the clinical advancement of UIP-620, a transdermal patch treatment for overactive bladder, and SS-262, a patch formulation for insomnia, alongside the development of dissolvable and coated microneedle applications for obesity and alopecia. Additionally, the company has completed major automation and efficiency upgrades at its main Sejong manufacturing plant to support margin expansion, broadened its overseas regulatory and distribution footprint in international markets, and strengthened executive governance through leadership realignments to concentrate capital and research capabilities on its core TDDS pharmaceutical technologies.